Table 2 Correlation between CD68 (IHC and mRNA) expression and clinic-pathological features of the patients
From: The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt
Characteristics | CD68 protein n(%) | P valuea | CD68 (mRNA) (n = 43) | P valueb | ||
|---|---|---|---|---|---|---|
Low (n = 15) | Moderate (n = 15) | High (n = 27) | n (%) | |||
Age | ||||||
< 40 | 7(46.7) | 7(46.7) | 9(33.3) | 0.13 | 17(39.5) | 0.1 |
≥ 40 | 8(53.3) | 8(53.3) | 18(67.7) | 26(60.5) | ||
Gender | ||||||
Male | 11(73.3) | 9(60.0) | 15(55.6) | 0.68 | 26(60.5) | 0.62 |
Female | 4(26.7) | 6(40.0) | 12(44.4) | 17(39.5) | ||
Stage | ||||||
I-II | 9(60.0) | 6(40.0) | 6(22.2) | 0.07 | 13(30.2) | 0.04* |
III-IV | 6(40.0) | 9(60.0) | 21(77.8) | 30(69.8) | ||
B-symptoms | ||||||
Negative | 10(66.7) | 11(73.3) | 17(63.0) | 0.24 | 30(69.8) | 0.51 |
Positive | 5(33.3) | 4(26.7) | 10(37.0) | 13(30.2) | ||
Bulky disease | ||||||
Negative | 13(86.7) | 12(80.0) | 22(81.5) | 0.95 | 35(81.4) | 0.98 |
Positive | 2(13.3) | 3(20.0) | 5(18.5) | 8(18.6) | ||
IPS | ||||||
Low risk <4 | 13(86.7) | 13(86.7) | 18(66.7) | 0.36 | 32(74.4) | 0.63 |
High risk ≥4 | 2(13.3) | 2(13.3) | 9(33.3) | 11(25.6) | ||
Pathology | ||||||
Mixed cellularity | 4(26.7) | 6(40.0) | 12(44.4) | 0.15 | 18(41.9) | 0.39 |
Nodular necrosis | 11(73.3) | 7(46.7) | 15(55.6) | 23(53.5) | ||
Lymphocyte-rich | 0(0.0) | 2(13.3) | 0(0.0) | 2(4.7) | ||
Lymphocyte-depleted | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | ||